Short answer
Gossamer Bio, Inc. (GOSS) filed an 8-K current report with the SEC on September 9, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). 1-for-80 reverse split effective September 10, 2026, with split-adjusted Nasdaq trading expected September 11 under “GOSS”.
Gossamer Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- 1-for-80 reverse split effective September 10, 2026, with split-adjusted Nasdaq trading expected September 11 under “GOSS”
- Primary objective: regain compliance with Nasdaq’s minimum bid-price requirement, though sustained compliance remains uncertain
- Authorized common shares reduced from 4 billion to 50 million, sharply limiting future issuance capacity
- Convertible notes, warrants, prefunded warrants and equity awards proportionately adjusted for the 1-for-80 ratio
- Fractional shares rounded up to whole shares, potentially modestly increasing post-split share count
Item EX-99.1 · Exhibit EX-99.1
- 1-for-80 reverse split effective September 10, 2026; split-adjusted trading begins September 11 under GOSS
- Primary objective: regain Nasdaq Global Select Market minimum bid-price compliance
- Authorized common shares reduced from 4,000,000,000 to 50,000,000
- Convertible notes, warrants, prefunded warrants, and equity awards proportionately adjusted
- Reverse split does not change proportional ownership, but sustained price compliance remains uncertain
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Gossamer Bio, Inc. 8-K filings
Get the next GOSS 8-K as it lands
Follow GOSS for push alerts, or ask the research agent what this filing means.